ArticleCellular and molecular life sciences : CMLS2026
ANGPTL8 accelerates bone loss in diabetic mice by promoting osteoclastic differentiation and inhibiting osteoblastic differentiation through AMPK pathway-mediated metabolic reprogramming.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Disruptions in energy metabolism within skeletal cells play a critical role in the pathogenesis of diabetic osteoporosis (DOP), primarily by affecting bone’s metabolic balance. The exact causes and regulatory mechanisms of these energy metabolism disorders in DOP remain unclear. Angiopoietin-like protein 8 (ANGPTL8), a protein involved in energy metabolism, is elevated in diabetics. This study aimed to investigate the role of ANGPTL8 in DOP development. In this study, a murine model of diabetic osteoporosis was developed, and an increase in plasma levels of ANGPTL8 was observed. The knockout of ANGPTL8 in diabetic mice mitigated osteoporosis, as demonstrated by micro-computed tomography (Micro-CT) analysis. Immunohistochemical analysis revealed that ANGPTL8 knockout increased the number of osteoblasts and decreased the number of osteoclasts in the femur. Moreover, in vitro cellular experiments demonstrated that ANGPTL8 inhibited the phosphorylation of AMPK through binding to PirB, resulting in decreased activity of the PFK1 enzyme and increased activity of the PDH enzyme. This metabolic modulation reduced glycolysis and increased oxidative phosphorylation within the cells. The alteration in metabolic pathways induced by ANGPTL8 suppressed the differentiation of osteoblastic precursor cells while facilitating the differentiation of osteoclastic precursor cells. In conclusion, ANGPTL8 alters energy metabolism to inhibit osteoblastic differentiation and promote osteoclastic differentiation by inhibiting the AMPK signaling pathway. This change in energy metabolism subsequently resulting in an imbalance between osteoblasts and osteoclasts, ultimately exacerbating diabetic osteoporosis. These findings provide new insights into DOP’s pathogenesis and suggest ANGPTL8 as a potential therapeutic target for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.